The FDA declined approval for Ultragenyx Pharmaceutical on July 14, 2025, citing manufacturing concerns. Analyst comments were also made on that day.
1 report, 1 independent
Updated Jul 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA declined approval for Ultragenyx Pharmaceutical on July 14, 2025, citing manufacturing concerns. Analyst comments were also made on that day.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Ultragenyx Pharmaceutical
biopharmaceutical company based in Novato, California, United States
Nothing else this week.
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Litigation regarding FDA approval process.
- Vance Thompson Vision advocated for standard product approval during an FDA committee meeting chaired by Michael X. Repka.
- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
Coverage
Newest first; wire copies grouped- BioPharma DiveFDA rejects Ultragenyx gene therapy over manufacturing concerns This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive n